PwC is facing internal anger in the US after telling staff it will stop paying for popular weight-loss drugs unless employees have diabetes, despite rising demand for the treatments. Employees discovered the change as they tried to renew their annual health benefits for the year and many were surprised by how sharply access was being tightened.
The cost of new GLP-1 medicines keeps climbing and employers are scrambling to contain health insurance bills. Many staff see the decision as a punchy shift in how the firm supports workers dealing with weight-related health issues.
Under the revised policy, which takes effect from July, PwC’s US health plans will no longer cover GLP-1 drugs when they are prescribed for weight loss, weight management or related conditions. Coverage remains only where employees have diabetes, effectively drawing a hard line between metabolic disease and obesity treatment.
The change places PwC among a growing number of large employers that are quietly adding restrictions to these fast-growing medication costs. Insurers and benefit managers have been warning that widespread use of GLP-1s can add substantial expense to corporate health plans.
Employees say the policy hits those already struggling with weight-linked health problems, especially in a profession known for long hours and high stress. Some staff argue that cutting off access until people develop diabetes ignores the preventative benefits of treating weight earlier.
Critics inside the firm frame the change as treating obesity as a lifestyle choice rather than a health condition, even as medical bodies increasingly recognise it as a chronic disease. Many workers now see benefit decisions as a test of an employer’s commitment to their wellbeing.
